FrancophonIA/ELRC3.0 huggingface dataset:
English: Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir can decrease exposures of medicinal products that are metabolized by CYP2C19 (e.g. lansoprazole, esomeprazole, smephenytoin), which may require dose adjustment/clinical monitoring.
Danish: Samtidig administration af dasabuvir og ombitasvir/paritaprevir/ritonavir kan reducere eksponeringen for lægemidler, der metaboliseres af CYP2C19 (f.eks. lansoprazol, esomeprazol, s-mephenytoin), hvilket kan nødvendiggøre dosisjustering/klinisk monitorering.
English: b. Includes subjects who discontinued due to adverse event, lost to follow-up or subject withdrawal, and subjects with reinfection
Danish: b. Omfatter alle forsøgspersoner, som stoppede behandlingen på grund af bivirkninger, som ikke blev fulgt op eller forsøgspersoner, som gik ud af studiet og forsøgspersoner med reinfektion.
English: Subjects with renal transplant and no cirrhosis were dosed for 12 weeks (with RBV for GT1a [n=9], without RBV for GT1b [n=3]).
Danish: Nyretransplanterede forsøgspersoner uden cirrose blev doseret i 12 uger (med RBV for GT1a [n = 9] uden RBV for GT1b [n = 3]).
English: Sulfamethoxazole, trimethoprim
Danish: Klinisk kommentar sulfamethoxazol, trimethoprim
English: The maximum daily dose of rosuvastatin should be 5 mg (see section 4.4).
Danish: Den daglige rosuvastatindosis må højst være 5 mg (se pkt.
English: Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir combines three direct-acting antiviral medicinal products with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle.
Danish: Ved samtidig administration af dasabuvir og ombitasvir/paritaprevir/ritonavir kombineres tre direkte virkende antivirale lægemidler med særskilte virkningsmekanismer og ikke-overlappende resistensprofiler, der er målrettet mod HCV i flere faser af den virale livscyklus.
English: Outcome for subjects without SVR12 On-treatment VF
Danish: Resultat for patienter uden SVR12 VF under behandling Recidiv
English: HMG CoA REDUCTASE INHIBITOR Rosuvastatin
Danish: HMG-CoA-REDUKTASEHÆMMER Rosuvastatin
English: In subjects with mild, moderate and severe hepatic impairment, dasabuvir AUC values were 17% higher, 16% lower and 325% higher, respectively.
Danish: Hos patienter med let, moderat og svært nedsat leverfunktion var AUC-værdierne for dasabuvir hhv. 17 % højere, 16 % lavere og 325 % højere.
English: The efficacy and safety of dasabuvir in combination with ombitasvir/paritaprevir/ritonavir with and without ribavirin was evaluated in eight Phase 3 clinical trials, including two trials exclusively in subjects with compensated cirrhosis (Child-Pugh A), in over 2,360 subjects with genotype 1 chronic hepatitis C infection as summarised in Table 6.
Danish: Virkningen af og sikkerheden ved dasabuvir i kombination med ombitasvir/paritaprevir/ritonavir med og uden ribavirin blev undersøgt i otte kliniske fase 3-studier, hvoraf det to udelukkende omfattede patienter med kompenseret cirrose (Child-Pugh A), og som tilsammen omfattede over 2.360 patienter med kronisk hepatitis C genotype 1-infektion (se tabel 6).
English: Following dosing of dasabuvir with ombitasvir/ paritaprevir /ritonavir, mean plasma half-life of dasabuvir was approximately 6 hours.
Danish: Efter administration af dasabuvir med ombitasvir/paritaprevir/ritonavir var den gennemsnitlige plasmahalveringstid for dasabuvir ca. 6 timer.
English: In the 67 genotype 1a infected subjects, NS3 variants were observed in 50 subjects, NS5A variants were observed in 46 subjects, NS5B variants were observed in 37 subjects, and treatmentemergent variants were seen in all 3 drug targets in 30 subjects.
Danish: Blandt de 67 genotype 1a-smittede forsøgspersoner blev der observeret NS3-varianter hos 50, NS5A-varianter hos 46 og NS5B-varianter hos 37; hos 30 forsøgspersoner sås behandlingsrelaterede varianter i alle 3 lægemiddelmål.
English: HIV ANTIVIRALS: INTEGRASE STRAND TRANSFER INHIBITOR Dolutegravir
Danish: HIV-ANTIVIRALE MIDLER: HIV-INTEGRASE TRANSFER-HÆMMER Dolutegravir
English: − Tablet core: microcrystalline cellulose (E 460(i)), lactose monohydrate, copovidone, croscarmellose sodium, colloidal anhydrous silica (E 551), magnesium stearate (E 470b).
Danish: − Tabletkerne: mikrokrystallinsk cellulose (E 460(i)), laktosemonohydrat, copovidon, croscarmellosenatrium, kolloid vandfri silica (E 551), magnesiumstearat (E 470b).
English: 24 weeks n/N % CIa n/N % CIa
Danish: 24 uger n/N % KIa n/N % KIa
English: The safety summary is based on pooled data from phase 2 and 3 clinical trials in subjects who received dasabuvir and ombitasvir/paritaprevir/ritonavir with or without ribavirin.
Danish: Sikkerhedsprofilen er baseret på samlede data fra kliniske fase 2- og fase 3-studier hos forsøgspersoner, der fik dasabuvir og ombitasvir/paritaprevir/ritonavir med eller uden ribavirin.
English: AMINOSALICYLATE Sulfasalazine
Danish: AMINOSALICYLATER Sulfasalazin
English: Refer to the Summary of Product Characteristics for ribavirin for additional information.
Danish: Se produktresuméet for ribavirin for yderligere oplysninger.
English: Overall SVR12 HCV genotype 1a HCV genotype 1b Outcome for subjects without SVR12 On-treatment VFa Relapse Otherb a. Confirmed HCV ≥ 25 IU/mL after HCV RNA < 25 IU/mL during treatment, confirmed 1 log10 IU/mL
Danish: Samlet SVR12 HCV genotype 1a HCV genotype 1b Resultat for patienter uden SVR12 VF under behandlinga Recidiv Andet a. Bekræftet HCV ≥ 25 IE/ml efter HCV-rna < 25 IE/ml under behandling, bekræftet 1 log10 IE/ml-stigning i
English: Concomitant use with efavirenz containing regimens is contraindicated (see section 4.3).
Danish: Samtidig brug af regimer med efavirenz er kontraindiceret (se pkt.
English: The overall safety profile in HCV-infected transplant recipients who were administered dasabuvir and ombitasvir/paritaprevir/ritonavir and ribavirin (in addition to their immunosuppressant medicinal products) was similar to subjects treated with dasabuvir and ombitasvir/paritaprevir/ritonavir and ribavirin in phase 3 clinical trials, although some adverse reactions were increased in frequency.
Danish: Den overordnede sikkerhedsprofil hos de HCV-smittede patienter med levertransplantat, der fik dasabuvir og ombitasvir/paritaprevir/ritonavir med ribavirin (i tillæg til deres immunsupprimerende medicin), var den samme som hos de forsøgspersoner, der fik dasabuvir og ombitasvir/paritaprevir/ritonavir med ribavirin i kliniske fase 3-studier, selvom visse bivirkninger forekom hyppigere.
English: NA No dose adjustment is necessary for zolpidem.
Danish: Ikke relevant Dosisjustering er ikke nødvendig for zolpidem.
English: Liver transplant recipients
Danish: Patienter med levertransplantat
English: Some patients may also take an antiviral medicine called ribavirin.
Danish: Nogle patienter skal også tage et antiviralt lægemiddel, der indeholder ribavirin.
English: 12 weeks N = 770 n (%)
Danish: 12 uger N = 770 n (%)
English: Relapse rates in GT1a cirrhotic subjects by baseline laboratory values are presented in Table 14.
Danish: Recidivraten hos patienter med genotype 1a og cirrose ud fra laboratorieværdier ved baseline præsenteres i tabel 14.
English: To maximise absorption, dasabuvir tablets should be taken with food, without regard to fat and calorie content (see section 5.2).
Danish: For at maksimere absorptionen skal dasabuvir-tabletterne tages sammen med mad; fedt- og kalorieindholdet er ligegyldigt (se pkt.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of multipack containing 56 (4 packs of 14) film-coated tablets - including blue box
Danish: MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE Ydre karton af multipakning, der indeholder 56 (4 æsker a 14) filmovertrukne tabletter - med blue box
English: Recommended co-administered medicinal product(s) and treatment duration for dasabuvir by patient population
Danish: Anbefalede samtidige administreret lægemidler og anbefalet behandlingsvarighed ved administration sammen med dasabuvir for hver patientpopulation
English: No dose adjustment of dasabuvir is required in patients with mild hepatic impairment (Child-Pugh A).
Danish: Det er ikke nødvendigt at justere dosis af dasabuvir hos patienter med let nedsat leverfunktion (ChildPugh A).
English: Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir together with medicinal products that are substrates of BCRP may increase plasma concentrations of these transporter substrates, potentially requiring dose adjustment/clinical monitoring.
Danish: Samtidig administration af dasabuvir sammen med ombitasvir/paritaprevir/ritonavir og og lægemidler, der er substrater af BCRP, kan øge plasmakoncentrationen af disse transportersubstrater og nødvendiggøre dosisjustering/klinisk overvågning.
English: Rilpivirine exposure is substantially increased (3-fold) when rilpivirine is given in combination with dasabuvir with ombitasvir/paritaprevir/ritonavir, with a consequent potential for QT-prolongation.
Danish: Rilpivirin-eksponeringen øges markant (med 3 gange), når rilpivirin administreres i kombination med dasabuvir med ombitasvir/paritaprevir/ritonavir, og risikoen for QT-forlængelse øges som følge deraf.
English: Co-administration of dasabuvir and ombitasvir/paritaprevir/ ritonavir with rilpivirine once daily should only be considered in patients without known QTprolongation, and without other QTprolongation coadministered medicinal products.
Danish: Samtidig administration af dasabuvir og ombitasvir/ paritatprevir/ritonavir med rilpivirin én gang dagligt bør kun overvejes hos patienter uden kendt QT-forlængelse, og som ikke får samtidig behandling med andre QTforlængende lægemidler.
English: Mechanism: increase in dasabuvir possibly due to CYP2C8 inhibition by trimethoprim ombitasvir
Danish: Mekanisme: Øget dasabuvireksponering skyldes muligvis CYP2C8hæmning af trimethoprim
English: Increase in paritaprevir exposures may be due to inhibition of OATPs by atazanavir.
Danish: Mekanisme: Øget paritaprevireksponering kan skyldes atazanavirs hæmning af OATP.
English: In another open-label phase 3b study evaluating 12 weeks of ombitasvir/paritaprevir/ritonavir with or without dasabuvir and without RBV in non-cirrhotic, treatment-naive GT1a and GT4 patients with CKD stage 4 or 5 (Ruby II), the SVR12 rate was 94.4% (17/18), with no subjects experiencing ontreatment virologic failure or relapse.
Danish: I et andet åbent fase 3b-studie med non-cirrose, der undersøgte 12 uger med ombitasvir/paritaprevir/ritonavir med eller uden dasabuvir og uden ribavirin hos behandlingsnaive GT1a- og GT4-patienter med CKD-stadium 4 eller 5 (Ruby-II), var SVR12-frekvensen 94,4% (17/18) og ingen patienter, der oplevede virologisk svigt eller tilbagefald af behandling.
English: Pharmacokinetic steady state for dasabuvir when coadministered with ombitasvir/paritaprevir/ritonavir is achieved after approximately 12 days of dosing.
Danish: Farmakokinetisk steady state for dasabuvir ved samtidig administration med ombitasvir/paritaprevir/ritonavir opnås efter ca. 12 dages dosering.
English: HIV ANTIVIRALS: PROTEASE INHIBITORS
Danish: HIV-ANTIVIRALE MIDLER: PROTEASEHÆMMERE
English: Lopinavir/ritonavir 400/100 mg twice daily or 800/200 mg once daily is contraindicated dasabuvir
Danish: Lopinavir/ritonavir 400/100 mg to gange dagligt eller 800/200 mg én gang dagligt er kontraindiceret på grund af øget paritatprevir
English: Dasabuvir M1 AUC values were 6% lower, 10% lower, and 13% lower, respectively.
Danish: AUC-værdierne for dasabuvirs metabolit M1 var hhv. 6 %, 10 % og 13 % lavere.
English: Clinical trials in peginterferon+ribavirin-experienced adults
Danish: Kliniske studier hos peginterferon/ribavirin-erfarne voksne
English: The SVR12 rates in HCV/HIV-1 co-infected subjects were thus consistent with SVR12 rates in the phase 3 trials of HCV mono-infected subjects.
Danish: SVR12-raterne hos HCV-forsøgspersoner med samtidig hiv-I-infektion var således konsistente med SVR12-raterne hos forsøgspersonerne i fase 3-studier, der kun var inficeret med HCV.
English: Overall SVR12 HCV genotype 1a Treatment naïve Prior pegIFN/RBV null responders Prior pegIFN/RBV partial responders Prior pegIFN/RBV Prior relapsers HCV genotype 1b Treatment naïve Prior pegIFN/RBV null responders Prior pegIFN/RBV partial responders Prior pegIFN/RBV Prior relapsers Outcome for subjects without SVR12 On-treatment VF Relapse Other a. 97.5% confidence intervals are used for the primary efficacy endpoints (overall SVR12 rate); 95% confidence intervals are used for additional efficacy endpoints (SVR12 rates in HCV genotype 1a and 1b-infected subjects).
Danish: Samlet SVR12 HCV genotype 1a Behandlingsnaive Tidligere ikke-respondere på pegIFN/RBV Tidligere delvise respondere på pegIFN/RBV Patienter med tidligere recidiv efter pegIFN/RBV-behandling HCV genotype 1b Behandlingsnaive Tidligere ikke-respondere på pegIFN/RBV Tidligere delvise respondere på pegIFN/RBV Patienter med tidligere recidiv efter pegIFN/RBV-behandling Resultat for patienter uden SVR12 VF under behandling Recidiv Andet a. 97,5 %-konfidensintervaller benyttes ved de primære effektmål (samlet SVR12-rate); 95 %konfidensintervaller benyttes ved yderligere effektmål (SVR12-rater hos HCV genotype 1a- og 1bsmittede patienter).
English: Co-administration of efavirenz (enzyme inducer) based regimens with paritaprevir /ritonavir + dasabuvir resulted in ALT elevations and therefore, early discontinuation of the study.
Danish: Regimer baseret på efavirenz (CYP3A4-inducer) administreret samtidig med paritaprevir/ritonavir + dasabuvir resulterede i forhøjet ALAT og dermed afslutning af studiet før tid.
English: Three interrupted dasabuvir and ombitasvir/paritaprevir/ritonavir for one to seven days, including one on ethinyloestradiol.
Danish: Tre afbrød behandlingen med dasabuvir og ombitasvir/paritaprevir/ritonavir i 1-7 dage, herunder én, der fik ethinyløstradiol.
English: The M1 metabolite of dasabuvir had EC50 values of 39 and 8 nM against genotype 1a-H77 and 1bCon1 strains in HCV replicon cell culture assays, respectively, and the activity of the M1 metabolite was attenuated 3- to 4-fold in the presence of 40% human plasma.
Danish: Dasabuvirs M1-metabolit havde EC50-værdier på henholdsvis 39 og 8 nM mod genotype 1a-H77- og 1b-Con1-stammer i HCV-replikon-cellekulturanalyser, og M1-metabolittens aktivitet blev 3-4 gange mindre under tilstedeværelse af 40 % humant plasma.
English: A side-by-side tabulation is provided to simplify presentation; direct comparisons should not be made across trials that differ in trial designs.
Danish: Ændringerne er opstillet ved siden af hinanden i tabelform for overblikkets skyld, men på grund af forskellige forsøgsdesign kan der ikke foretages direkte sammenligninger.
English: Monitor ciclosporin levels and adjust dose and/or dosing frequency as needed.
Danish: Overvåg ciclosporinniveauet, og justér dosis og/eller doseringshyppighed efter behov.
English: Tell your doctor or pharmacist before taking Exviera if you are also using hormonal contraceptives.
Danish: Du skal også tale med lægen eller apotekspersonalet, før du tager Exviera, hvis du tager hormonale præventionsmidler.
English: NA No dose adjustment is necessary for escitalopram.
Danish: Ikke relevant Dosisjustering er ikke nødvendig for escitalopram.
English: A reduction of hydrocodone dose by 50% and/or clinical monitoring should be considered when administered with dasabuvir + ombitasvir/paritaprevir /ritonavir.
Danish: hydrokodon-dosis med 50% og/eller klinisk monitorering bør overvejes ved samtidig administration med dasabuvir + ombitasvir/paritaprevir/ri tonavir.
English: ↑ naloxone
Danish: ↑ naloxon
English: RUBY-I; treatment-naïve or pegIFN + RBV experienced with or without cirrhosis who have severe renal impairment or end stage renal disease (ESRD)
Danish: RUBY-I; behandlingsnaive eller pegIFN + ribavirin erfarne med eller uden cirrose, der har alvorlig nedsat nyrefunktion eller end-stage renal disease (ESRD)
English: The persistence of dasabuvir, ombitasvir and paritaprevir resistance-associated amino acid substitutions in NS5B, NS5A and NS3, respectively, was assessed in genotype 1a-infected subjects in Phase 2b trials.
Danish: Persistensen af dasabuvir-, ombitasvir- og paritaprevir-resistensrelaterede aminosyresubstitutioner i henholdsvis NS5B, NS5A og NS3 blev undersøgt hos genotype 1a-smittede forsøgspersoner i fase 2bstudier.
English: Beginning the day after dasabuvir and ombitasvir/paritaprevir/ ritonavir are initiated; reinitiate tacrolimus at a reduced dose based on tacrolimus blood concentrations.
Danish: Start dagen efter dasabuvir og ombitasvir/paritaprevir/ri tonavir behandling er indledt; genstart tacrolimus med reduceret dosis baseret på tacrolimus blodkoncentration.
English: Two patients discontinued dasabuvir and ombitasvir/paritaprevir/ritonavir due to elevated ALT, including one on ethinyloestradiol.
Danish: To patienter seponerede dasabuvir og ombitasvir/paritaprevir/ritonavir på grund af forhøjet ALAT, herunder én, der fik ethinyløstradiol.
English: Dasabuvir administered with ombitasvir/paritaprevir/ritonavir did not affect the exposures of the CYP2D6 /CYP1A2 substrate duloxetine.
Danish: Dasabuvir administreret sammen med ombitasvir/paritaprevir/ritonavir havde ingen indvirkning på eksponeringen for CYP2D6/CYP1A2-substratet duloxetin.
English: HIV ANTIVIRALS: NUCLEOSIDE INHIBITORS Abacavir/ lamivudine
Danish: HIV-ANTIVIRALE MIDLER: NUKLEOSID-HÆMMERE Abacavir/ lamivudin
English: Medicinal products transported by the OATP family Refer to the ombitasvir/paritaprevir/ritonavir Summary of Product Characteristics for details on OATP1B1, OATP1B3 and OATP2B1 substrates (see also Table 2).
Danish: Se produktresuméerne for ombitasvir/paritaprevir/ritonavir vedrørende OATP1B1-, OATP1B3- og OATP2B1-substrater (se også tabel 2).
English: Each carton contains 56 tablets (multipack carton containing 4 inner cartons of 14 tablets).
Danish: Hver æske indeholder 56 tabletter (multipakning med 4 æsker a 14 tabletter).
English: No subjects with HCV genotype 1b infection experienced on-treatment virologic failure and 2 subjects with HCV genotype 1b infection experienced relapse.
Danish: Ingen patienter med HCV genotype 1b-infektion oplevede virologisk svigt under behandling, og 2 patienter med HCV genotype 1b-infektion fik recidiv.
English: Serious and/or life threatening events have been observed with co-administration of dasabuvir and ombitasvir/paritaprevir/ritonavir with systemic tacrolimus, and a similar risk can be expected with sirolimus and everolimus.
Danish: Ved samtidig administration af dasabuvir og ombitasvir/paritaprevir/ritonavir med systemisk tacrolimus er alvorlige og/eller livstruende hændelser observeret, og en lignende risiko kan forventes med sirolimus og everolimus.
English: In vitro studies show that dasabuvir is not an inhibitor of organic cation transporters (OCT2), organic anion transporters (OAT3), or multidrug and toxin extrusion proteins (MATE1 and MATE2K) at clinically relevant concentrations.
Danish: In vitro-studier har vist, at dasabuvir ikke hæmmer den organiske kationtransporter (OCT2), den organiske aniontransporter (OAT3) eller multilægemiddelog toksinekstrusionsproteinerne (MATE1 og MATE2K) ved klinisk relevante koncentrationer.
English: In biochemical assays, dasabuvir inhibited a panel of genotype 1a and 1b polymerases with a mean IC50 value of 4.2 nM (range 2.2 to 10.7 nM; n=7).
Danish: I biokemiske analyser hæmmede dasabuvir et panel af genotype 1a- og 1b-polymeraser med en gennemsnitlig IC50-værdi på 4,2 nM (interval: 2,2-10,7 nM; n = 7).
English: Patients receiving ribavirin should also refer to the Summary of Product Characteristics of ribavirin.
Danish: Hvis patienten får ribavirin, skal man også henholde sig til produktresuméet for ribavirin.
English: The recommended co-administered medicinal product(s) and treatment duration for dasabuvir combination therapy are provided in Table 1.
Danish: De anbefalede samtidige administreret lægemidler og den anbefalede behandlingsvarighed ved administration sammen med dasabuvir er angivet i tabel 1.
English: Dasabuvir and ombitasvir/paritaprevir/ritonavir with or without ribavirin were assessed in 68 subjects with genotype 1 infection with or without cirrhosis who have severe renal impairment or ESRD (see Section 5.1).
Danish: Dasabuvir og ombitasvir/paritaprevir/ritonavir med eller uden ribavirin blev undersøgt i 68 patienter med genotype 1-infektion med eller uden cirrose, der havde alvorlig nedsat nyrefunktion eller ESRD (se pkt.
English: Patients with moderate to severe hepatic impairment (Child-Pugh B or C) (see section 5.2).
Danish: Patienter med moderat til alvorlig nedsat leverfunktion (Child-Pugh B eller C), (se pkt.
English: Co-administration of dasabuvir and ombitasvir/paritaprevir/ritonavir with systemic tacrolimus, sirolimus or everolimus increases the concentrations of the immunosuppressant due to CYP3A inhibition by ritonavir (see section 4.5).
Danish: Samtidig administration af dasabuvir og ombitasvir/paritaprevir/ritonavir med systemisk tacrolimus, sirolimus eller everolimus øger koncentrationen af immunsuppresiva på grund af CYP3A hæmning af ritonavir (se pkt.
English: Lopinavir/ritonavir 800/200 mg once daily (administered in the evening) was also administered with dasabuvir with ombitasvir/paritaprevir/ritonavir.
Danish: Lopinavir/ritonavir 800/200 mg én gang dagligt (om aftenen) blev også administreret sammen med dasabuvir med ombitasvir/paritaprevir/ritonavir.
English: No subjects with HCV genotype 1b infection experienced on-treatment virologic failure and one subject with HCV genotype 1b infection experienced relapse.
Danish: Ingen patienter med HCV genotype 1b-infektion oplevede virologisk svigt under behandling, og én patient med HCV genotype 1b-infektion fik recidiv.
English: NA No dose adjustment is necessary for duloxetine.
Danish: Ikke relevant Dosisjustering er ikke nødvendig for duloxetin.
English: Theoretically, dasabuvir with ombitasvir/paritaprevir/ritonavir is expected to increase the exposure to pitavastatin and fluvastatin.
Danish: Teoretisk set forventes dasabuvir med ombitasvir/paritaprevir/ritonavir at øge eksponeringen for pitavastatin og fluvastatin.
English: Diabetics may experience improved glucose control, potentially resulting in symptomatic hypoglycaemia, after initiating HCV direct acting antiviral treatment.
Danish: Patienter med diabetes kan opleve forbedret blodsukkerkontrol efter påbegyndelse af HCV-behandling med direkte virkende antivirale lægemidler/DAA'er, hvilket potentielt kan resultere i symptomatisk hypoglykæmi.
English: Dasabuvir was not carcinogenic in a 6-month transgenic mouse study up to the highest dosage tested (2 g/kg/day), resulting in dasabuvir AUC exposures approximately 19-fold higher than those in humans at the recommended dose of 500 mg (250 mg twice daily).
Danish: I et 6-måneders studie med transgene mus var dasabuvir ikke karcinogent ved doser op til den højeste testede dosis (2 g/kg/dag), dvs. en dasabuvir-eksponering (målt ud fra AUC), der var ca. 39 gange højere end hos mennesker ved den anbefalede daglige dosis på 500 mg (250 mg to gange dagligt).
English: The pharmacokinetics of dasabuvir with ombitasvir/paritaprevir/ritonavir in paediatric patients has not been investigated (see section 4.2).
Danish: Farmakokinetikken for dasubavir med ombitasvir/paritaprevir/ritonavir hos pædiatriske patienter er ikke undersøgt (se pkt.
English: Transient elevations in serum bilirubin (predominantly indirect) were observed in subjects receiving dasabuvir and ombitasvir/paritaprevir/ritonavir with ribavirin, related to the inhibition of the bilirubin transporters OATP1B1/1B3 by paritaprevir and ribavirin-induced haemolysis.
Danish: Forbigående forhøjet serum-bilirubin (hovedsagelig ikke-konjugeret (indirekte) bilirubin) sås hos forsøgspersoner, der fik dasabuvir og ombitasvir/paritaprevir/ritonavir med ribavirin, idet dette var forbundet med paritaprevirs hæmning af bilirubintransporterne OATP1B1/1B3 og ribavirin-induceret hæmolyse.
English: Methadone
Danish: metadon
English: Ethinyloestradiol is contraindicated in combination with dasabuvir (see section 4.3).
Danish: Ethinyløstradiol er kontraindiceret i kombination med dasabuvir (se pkt.